GlobeNewsWire · NIU · October 21, 2026

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Get the app for more

Explore stock news, insights and company research.